CD24Fc预防移植物抗宿主病的2期试验
这项2a期多中心研究评估了CD24Fc联合他克莫司和甲氨蝶呤预防接受清髓性无关供者造血干细胞移植的血液恶性肿瘤成人患者急性GVHD的药代动力学、安全性和疗效。CD24Fc扩展队列(多剂量)第180天3-4级急性GVHD无病生存率为96.2%(95%CI 75.7-99.4),匹配对照组为73.6%(95%CI 63.2-81.4),风险比0.1(95%CI 0.0-0.6),log-rank检验P=0.03;未发生剂量限制性毒性。
要点
- CD24Fc多剂量方案第180天3-4级急性GVHD无病生存率96.2%,匹配对照组73.6%(HR 0.1,P=0.03)。
- CD24Fc剂量递增和扩展阶段均未发生剂量限制性毒性。
- 多剂量CD24Fc药效持久,安全性结局与单剂量方案相似。
核心结论
- CD24Fc多剂量方案耐受良好且无剂量限制性毒性,与清髓性无关供者造血干细胞移植后较高的严重急性GVHD无病生存率相关。
研究设计与样本
- 2a期多中心研究,采用双盲、安慰剂对照、剂量递增阶段确定推荐剂量,随后进行开放标签扩展阶段并设匹配对照,评估CD24Fc联合他克莫司和甲氨蝶呤预防急性GVHD的药代动力学、安全性和疗效。
- 研究对象为接受清髓性预处理的人类白细胞抗原匹配无关供者造血干细胞移植的血液恶性肿瘤成人患者。
- 试验在ClinicalTrials.gov注册,注册号为NCT02663622。
主要发现
- CD24Fc扩展队列(多剂量)第180天3-4级急性GVHD无病生存率为96.2%(95%CI 75.7-99.4)。
- 匹配对照组第180天3-4级急性GVHD无病生存率为73.6%(95%CI 63.2-81.4),CD24Fc扩展队列较匹配对照组升高(HR 0.1,95%CI 0.0-0.6;log-rank检验P=0.03)。
- CD24Fc剂量递增或扩展阶段均无参与者发生剂量限制性毒性。
- 多剂量CD24Fc方案药效持久,与单剂量方案相比安全性结局相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients who undergo human leukocyte antigen-matched unrelated donor (MUD) allogeneic hematopoietic stem cell transplantation (HSCT) with myeloablative conditioning for hematologic malignancies often develop acute graft-versus-host disease (GVHD) despite standard calcineurin inhibitor-based prophylaxis in combination with methotrexate. This trial evaluated a novel human CD24 fusion protein (CD24Fc/MK-7110) that selectively targets and mitigates inflammation due to damage-associated molecular patterns underlying acute GVHD while preserving protective immunity after myeloablative conditioning. This phase 2a, multicenter study evaluated the pharmacokinetics, safety, and efficacy of CD24Fc in combination with tacrolimus and methotrexate in preventing acute GVHD in adults undergoing MUD HSCT for hematologic malignancies. A double-blind, placebo-controlled, dose-escalation phase to identify a recommended dose was followed by an open-label expansion phase with matched controls to further evaluate the efficacy and safety of CD24Fc in preventing acute GVHD. A multidose regimen of CD24Fc produced sustained drug exposure with similar safety outcomes when compared with single-dose regimens. Grade 3 to 4 acute GVHD-free survival at day 180 was 96.2% (95% confidence interval [CI], 75.7-99.4) in the CD24Fc expansion cohort (CD24Fc multidose), compared with 73.6% (95% CI, 63.2-81.4) in matched controls (hazard ratio, 0.1 [95% CI, 0.0-0.6]; log-rank test, P = .03). No participants in the CD24Fc escalation or expansion phases experienced dose-limiting toxicities (DLTs). The multidose regimen of CD24Fc was well tolerated with no DLTs and was associated with high rates of severe acute GVHD-free survival after myeloablative MUD HSCT. This trial was registered at ClinicalTrials.gov as #NCT02663622.
引用
- Magenau J, Jaglowski S, Uberti J, et al. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024. PMID: 37647633. doi:10.1182/blood.2023020250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。